For the Inventor, By the Inventor

Enter assignee name

Ness Ziona, Israel

Amorphical Ltd.

Calculating rank

USPTO Granted Patents = 21

CIPO Patents = 1

EPO Patents = 10

Trademarks = 2

Forward Citations = 18

Loading Chart...

Loading Chart...

20 inventors (with patents filed for the assignee):

Yosef Ben (13 out of 14 patents)

Yigal Dov Blum (10 out of 40 patents)

Abraham Shahar (4 out of 4 patents)

4. Amir Arav (4 out of 13 patents)

5. Assaf Shechter (4 out of 7 patents)

6. Amir Sagi (4 out of 12 patents)

7. Oren Meiron (4 out of 4 patents)

8. Sharon Hershkovitz (3 out of 3 patents)

9. Hagay Moshe (2 out of 2 patents)

10. Ben Ashkenazi (2 out of 2 patents)

11. Galit Shaltiel-Gold (2 out of 2 patents)

12. Michal Daniely (2 out of 2 patents)

13. Shmuel Bentov (2 out of 2 patents)

14. Amir Berman (2 out of 3 patents)

15. Binyamin Ashkenazi (2 out of 2 patents)

21 patents: Sort by Forward Citations

1. 12760277 - Stabilized amorphous calcium carbonate as a supplement for cell culture media (2026-10-13),

2. 12714726 - Encapsulated amorphous calcium carbonate compositions (2026-08-25),

3. 12629390 - Stabilized amorphous calcium carbonate for treatment of neurological, muscular and infertility diseases or conditions (2026-05-19),

4. 12357656 - Amorphous calcium carbonate for improving athletic performance (2025-07-15),

5. 12121538 - Compositions of amorphous calcium carbonate for inhalation, sublingual or buccal administration (2024-10-22),

6. 12115184 - Amorphous calcium carbonate stabilized with polyphosphates or bisphosphonates (2024-10-15),

7. 12060573 - Stabilized amorphous calcium carbonate as a supplement for cell culture media (2024-08-13),

8. 11602542 - Non-aqueous liquid and semi-solid formulations of amorphous calcium carbonate (2023-03-14),

9. 11446327 - Encapsulated amorphous calcium carbonate compositions (2022-09-20),

10. 11207347 - Stabilized amorphous calcium carbonate for treatment of neurological, muscular and infertility diseases or conditions (2021-12-28),

11. 11052108 - Amorphous calcium carbonate for treating a leukemia (2021-07-06),

12. 11052107 - Amorphous calcium carbonate stabilized with polyphosphates or bisphosphonates (2021-07-06),

13. 11033576 - Compositions of amorphous calcium carbonate for inhalation, sublingual or buccal administration (2021-06-15),

14. 10758566 - Stabilized amorphous calcium carbonate for treatment of neurological, muscular and infertility diseases or conditions (2020-09-01),

15. 10758565 - Compositions of amorphous calcium carbonate for inhalation, sublingual or buccal administration (2020-09-01),

Company Overview

Amorphical Ltd. is a technology company based in Ness Ziona, Israel, specializing in advanced materials and nanotechnology. The organization focuses on developing innovative solutions that enhance the performance and functionality of various applications, particularly in the fields of electronics and energy. By leveraging cutting-edge research, Amorphical aims to push the boundaries of material science, contributing to advancements in industries such as semiconductors and renewable energy, thereby fostering sustainable technological progress.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Nov 10 2026

21 Patents

#4 in Ness Ziona

#291 in Israel

#30,080 in the World

Ness Ziona, Israel

Amorphical Ltd.

Forward Citations = 18

20 inventors:

Yosef Ben (13 out of 14 patents)

Yigal Dov Blum (10 out of 40 patents)

Abraham Shahar (4 out of 4 patents)

4. Amir Arav (4 out of 13 patents)

5. Assaf Shechter (4 out of 7 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Amorphical Ltd.. Retrieved from https://idiyas.com/company/amorphical

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…